Neovasc Inc (US) (NASDAQ: NVCN) is one of 78 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its competitors? We will compare Neovasc Inc (US) to related companies based on the strength of its risk, earnings, profitability, analyst recommendations, institutional ownership, dividends and valuation.
This is a summary of current ratings for Neovasc Inc (US) and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Neovasc Inc (US)||0||0||3||0||3.00|
|Neovasc Inc (US) Competitors||327||1949||3445||111||2.57|
Neovasc Inc (US) presently has a consensus target price of $4.50, suggesting a potential upside of 742.85%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 4.44%. Given Neovasc Inc (US)’s stronger consensus rating and higher possible upside, analysts clearly believe Neovasc Inc (US) is more favorable than its competitors.
Risk & Volatility
Neovasc Inc (US) has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Comparatively, Neovasc Inc (US)’s competitors have a beta of 1.49, suggesting that their average share price is 49% more volatile than the S&P 500.
Insider & Institutional Ownership
19.0% of Neovasc Inc (US) shares are held by institutional investors. Comparatively, 51.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Neovasc Inc (US) and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Neovasc Inc (US)||$9.51 million||-$86.49 million||2.22|
|Neovasc Inc (US) Competitors||$2.14 billion||$234.27 million||-96.36|
Neovasc Inc (US)’s competitors have higher revenue and earnings than Neovasc Inc (US). Neovasc Inc (US) is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Neovasc Inc (US) and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Neovasc Inc (US)||268.35%||-85.81%||23.39%|
|Neovasc Inc (US) Competitors||-154.31%||-19.90%||-8.56%|
Neovasc Inc (US) competitors beat Neovasc Inc (US) on 7 of the 13 factors compared.
About Neovasc Inc (US)
Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with MarketBeat.com's FREE daily email newsletter.